Jency Vathikulam, DO
Family Medicine · Forney, TXNPI 1790122562
Payments from drug & device makers
Across 224 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$581
- Novo Nordisk$378
- AstraZeneca$268
- Abbott$214
- Merck$202
- Amarin Pharma, Inc.$182
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,578100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $581 |
| Novo Nordisk | 24 | $378 |
| AstraZeneca | 19 | $268 |
| Abbott | 10 | $214 |
| Merck | 15 | $202 |
| Amarin Pharma, Inc. | 9 | $182 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $178 |
| Amgen | 10 | $175 |
| Pfizer | 10 | $159 |
| Lilly USA, LLC | 9 | $127 |
| Boehringer Ingelheim | 8 | $124 |
| Sanofi-aventis U.S. LLC | 7 | $116 |
| GSK | 7 | $105 |
| Genentech USA, Inc. | 4 | $73 |
| Kowa Pharmaceuticals America, Inc. | 5 | $72 |
| Novartis | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $56 |
| Eisai Inc. | 4 | $55 |
| Exact Sciences | 3 | $55 |
| Astellas Pharma US Inc | 3 | $49 |
| Ironwood Pharmaceuticals, Inc | 3 | $47 |
| Corcept Therapeutics | 1 | $42 |
| Johnson & Johnson | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Bayer | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $19 |
| Lundbeck LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Circassia Inc. | 1 | $11 |
How this compares
$3,578 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $81,761 |
| JanuviaSitagliptin Phosphate | 45 | $59,633 |
| FarxigaDapagliflozin Propanediol | 33 | $46,118 |
| EliquisApixaban | 28 | $39,343 |
| JardianceEmpagliflozin | 30 | $37,911 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $13,890 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $13,491 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $8,707 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $7,067 |
| Sucralfate | 17 | $3,437 |
| Duloxetine Hcl | 90 | $3,362 |
| Atorvastatin Calcium | 327 | $3,319 |
| Ezetimibe | 84 | $3,152 |
| Gabapentin | 190 | $2,886 |
| Levothyroxine Sodium | 292 | $2,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $378 | $81,76158 claims |
| MerckJanuvia | $202 | $59,63345 claims |
| AstraZenecaFarxiga, Symbicort | $268 | $48,71946 claims |
| PfizerEliquis | $159 | $39,34328 claims |
| Boehringer IngelheimJardiance | $124 | $37,91130 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $105 | $22,19827 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $116 | $13,89012 claims |
| AbbVieSynthroid | $581 | $1,75420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Forney
- Shilpi MittalForney$2.5M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.